Patrick Enright Purchases 5,882 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick Enright acquired 5,882 shares of the stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $42.50 per share, with a total value of $249,985.00. Following the completion of the purchase, the director owned 5,882 shares of the company’s stock, valued at approximately $249,985. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Vera Therapeutics Stock Down 1.8%

NASDAQ VERA opened at $48.30 on Wednesday. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.19. The stock has a market capitalization of $3.09 billion, a PE ratio of -12.11 and a beta of 1.21. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. The business’s 50-day moving average is $32.77 and its 200 day moving average is $26.87.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same quarter last year, the company earned ($0.85) earnings per share. Sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds have recently bought and sold shares of VERA. Quantbot Technologies LP bought a new stake in shares of Vera Therapeutics in the 2nd quarter worth approximately $51,000. Quarry LP raised its position in shares of Vera Therapeutics by 25.0% in the 1st quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $60,000 after purchasing an additional 500 shares during the last quarter. AlphaQuest LLC boosted its stake in Vera Therapeutics by 404.7% in the 1st quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock worth $96,000 after purchasing an additional 3,213 shares in the last quarter. Virtus Investment Advisers LLC lifted its stake in shares of Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after buying an additional 539 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after acquiring an additional 2,757 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Evercore ISI raised their price target on Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. Wedbush boosted their price target on shares of Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. JPMorgan Chase & Co. decreased their price target on shares of Vera Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a research note on Friday, November 7th. Finally, Pivotal Research set a $73.00 price objective on Vera Therapeutics in a research report on Friday, December 5th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $66.58.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.